Purchase Order 12405B23P0219
- Not listed
- The U.S. government awarded a $12,411.55 firm fixed-price purchase order to Genscript USA Inc. on September 15, 2021, for animal immunization, cell fusion, subcloning, antibody production, purification, and sequencing services. The contract, which was completed on March 16, 2022, was funded through a civilian federal agency within the Southeast Area and performed at Genscript's facility in Piscataway, New Jersey. No set-aside designation was applied to this award. Genscript USA Inc., a...
- The U.S. government awarded a purchase order valued at $5,075.85 to Genscript USA Inc., a biotechnology company headquartered in Piscataway, New Jersey, for monoclonal antibody products. The contract, awarded on September 19, 2016, with an ultimate completion date of March 20, 2017, was issued under a firm fixed-price pricing structure by a civilian federal agency (Southeast Area). No set-aside designation was applied to this award. The place of performance is located in Piscataway, New...
- The U.S. Department of Agriculture (USDA) awarded a $6,701.14 firm fixed-price purchase order to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the production of antibodies against avian herpesvirus antigens, which supports USDA's animal disease monitoring and research efforts. This award is part of a larger $1.5 million blanket purchase agreement (BPA) between Genscript and USDA's Animal and Plant Health Inspection Service (APHIS) to provide...
- This federal contract award was issued by the Midwest Area component of a civilian federal agency to Genscript USA Inc., a biotechnology company based in New Jersey. The $13,420.52 firm fixed-price purchase order is for the supply of proteins and antibodies. The contract does not have a set-aside designation. Genscript is a provider of specialized molecular biology products and services to various government agencies, including the Department of Health and Human Services, Department of...
- This $8,435.16 firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services' National Institutes of Health, to Genscript USA Inc., a for-profit biotechnology company located in Piscataway, New Jersey. The contract is for antibody production services, with a completion date of June 15, 2018. Genscript specializes in providing a range of biomedical research and public health products and services to...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $164,700.00 firm fixed-price purchase order is for monoclonal antibodies and plasmids services, with a completion date of June 14, 2026. The contract does not have a set-aside designation. Genscript is a key supplier of...
- This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract, valued at $3,800.00, is for custom monoclonal antibody production services to support NIAID's biomedical research and public health initiatives. This contract does not have a set-aside designation. Genscript...
- This federal contract was awarded by the Plains Area division of a civilian federal agency to Genscript USA Inc., a biotechnology company based in New Jersey. The $3,458.11 firm fixed-price purchase order is for protein expression and purification services. The contract does not have a set-aside designation. Genscript has received numerous prime and subcontract awards from federal agencies like the Department of Health and Human Services (including the National Institutes of Health, Centers...
- The U.S. Department of Agriculture awarded a $22,817.95 firm fixed-price purchase order to Genscript USA Inc. on September 15, 2017, for Calonectria antibody production based on GenScript Quote #1410287 dated October 10, 2017. The contract, with an ultimate completion date of September 30, 2019, was issued without a set-aside designation. Work will be performed at the contractor's facility in Piscataway, New Jersey. This award supports APHIS' (Animal and Plant Health Inspection Service) research...
- This firm fixed-price purchase order, valued at $16,215, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support NIAID's biomedical research and public health initiatives. Genscript, a for-profit organization, has received numerous prime...
The U.S. government awarded a $6,576.20 firm fixed-price purchase order to Genscript USA Inc. for the production of rabbit polyclonal antibodies against the chicken PCD1-1 immunoglobulin V domain. The contract, awarded on June 12, 2023, with an ultimate completion date of December 29, 2023, was funded by a civilian Southeast Area agency. Work is to be performed in East Lansing, Michigan. This contract represents a non-set-aside award to the Piscataway, New Jersey-based biotechnology firm, which specializes in advanced molecular biology services including antibody development, gene synthesis, and protein production. Genscript USA Inc. is an established federal contractor with a strong track record supporting health-related agencies including the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, and Department of Agriculture. The company has been registered in the System for Award Management since July 2013 and holds significant blanket purchase agreements, including a $1.5 million USDA Animal and Plant Health Inspection Service agreement. The production of polyclonal antibodies under this purchase order aligns with Genscript's core competencies in custom antibody development and supports the government's broader research and diagnostic capabilities in life sciences and biomedical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.6k | 6/11/23 |